DAVID M. GORSON
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
- Where
- Bennington, VT
- NPI
- 1194773200
- Received
- $34,994 in 20 records, 2019 to 2020 ($4,973 general, $30,021 research)
- As principal investigator
- $13,480 of research payments to others in 2 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | Research payment | 1 | $2,530 |
| 2019 | General payment | 3 | $4,973 |
| 2019 | Research payment | 16 | $27,491 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Novo Nordisk AS | 10 | $20,191 | 2019 |
| SANOFI US SERVICES INC. | 7 | $9,830 | 2019–2020 |
| Novo Nordisk Inc | 3 | $4,973 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 17 | $30,021 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $4,941 |
| Education | 1 | $32 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-01-27 | SANOFI US SERVICES INC. | $2,530 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2020 | |
| 2019-10-02 | SANOFI US SERVICES INC. | $600 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-08-30 | Novo Nordisk AS | $1,000 | Research payment | Cash or cash equivalent | FIASP Drug, Diabetes | NN1218-4113 | 2019 |
| 2019-08-30 | Novo Nordisk AS | $1,000 | Research payment | Cash or cash equivalent | FIASP Drug, Diabetes | NN1218-4113 | 2019 |
| 2019-08-26 | SANOFI US SERVICES INC. | $1,050 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-08-06 | Novo Nordisk AS | $8,181 | Research payment | Cash or cash equivalent | Tresiba Drug, Diabetes | NN1250-4252 | 2019 |
| 2019-08-06 | Novo Nordisk AS | $1,000 | Research payment | Cash or cash equivalent | Tresiba Drug, Diabetes | NN1250-4252 | 2019 |
| 2019-07-29 | SANOFI US SERVICES INC. | $300 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-07-02 | SANOFI US SERVICES INC. | $1,600 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-06-25 | Novo Nordisk AS | $5,459 | Research payment | Cash or cash equivalent | FIASP Drug, Diabetes | NN1218-4113 | 2019 |
| 2019-06-12 | Novo Nordisk Inc | $229 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-05-29 | SANOFI US SERVICES INC. | $1,475 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-03-29 | Novo Nordisk AS | $161 | Research payment | Cash or cash equivalent | FIASP Drug, Diabetes | NN1218-4113 | 2019 |
| 2019-03-05 | Novo Nordisk AS | $500 | Research payment | Cash or cash equivalent | FIASP Drug, Diabetes | NN1218-4113 | 2019 |
| 2019-03-05 | Novo Nordisk Inc | $32 | Education | In-kind items and services | 2019 | ||
| 2019-03-02 | Novo Nordisk Inc | $4,711 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Tresiba Drug, Diabetes | 2019 | |
| 2019-02-21 | Novo Nordisk AS | $434 | Research payment | Cash or cash equivalent | Tresiba Drug, Diabetes | NN1250-4252 | 2019 |
| 2019-02-11 | SANOFI US SERVICES INC. | $2,275 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-01-24 | Novo Nordisk AS | $1,722 | Research payment | Cash or cash equivalent | Tresiba Drug, Diabetes | NN1250-4252 | 2019 |
| 2019-01-24 | Novo Nordisk AS | $732 | Research payment | Cash or cash equivalent | FIASP Drug, Diabetes | NN1218-4113 | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2020-08-31 | Lexicon Pharmaceuticals, Inc. | DAVID GORSON MD | $3,000 | EFC-14875 | 2020 |
| 2019-03-07 | AstraZeneca Pharmaceuticals LP | David M Gorson, Md | $10,480 | Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Eval | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Bennington, VT, county Bennington County, VT, state Vermont; placed by its city name.
| Measure | Place (city or town) Bennington, VT | County Bennington County, VT | State Vermont |
|---|---|---|---|
| Population B01003 | 9,245 | 37,269 | 647,106 |
| Population, 2020 census P1 | 8,795 | 37,347 | 643,077 |
| Median age B01002 | 44.5 | 46.9 | 43.1 |
| Under 18 B01001 | 15.8% | 18.7% | 17.9% |
| 65 and over B01001 | 26.9% | 24.4% | 21.4% |
| Households B11001 | 4,043 | 14,987 | 273,416 |
| Foreign born B05002 | 2.8% | 2.7% | 4.3% |
| Median household income B19013 | $54,257 | $73,325 | $81,203 |
| Median family income B19113 | $82,448 | $101,142 | $105,211 |
| Per capita income B19301 | $34,705 | $46,487 | $46,500 |
| Poverty rate B17001 | 11.4% | 11.3% | 10.1% |
| Unemployment rate B23025 | 5.4% | 4.4% | 3.6% |
| Civilian labor force B23025 | 4,175 | 18,587 | 352,132 |
| Mean commute (minutes) B08013 | 17.2 | 20.3 | 23.5 |
| Bachelor's degree or higher B15003 | 34.5% | 41.8% | 43.8% |
| Housing units B25001 | 4,340 | 20,903 | 339,042 |
| Owner-occupied B25003 | 54.7% | 73.7% | 73.2% |
| Renters B25003 | 45.3% | 26.3% | 26.8% |
| Median home value B25077 | $191,700 | $279,900 | $316,600 |
| Median gross rent B25064 | $1,115 | $1,109 | $1,234 |
| White, not Hispanic B03002 | 90.1% | 90.8% | 89.9% |
| Black B03002 | 0.5% | 1.1% | 1.1% |
| Hispanic or Latino B03002 | 2.6% | 2.8% | 2.6% |
| Asian B03002 | 1.2% | 0.9% | 1.8% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Bennington, VT.
Comments